Atenolol

Cardiovascular diseases such as hypertension and coronary heart disease are the leading causes of death globally. As first-line antihypertensive drugs, β-blockers occupy a core position in the whole-course management of cardiovascular diseases. Atenolol is a selective β₁ adrenoceptor blocker. It can reduce myocardial contractility, slow down heart rate and decrease cardiac output by blocking β₁ receptors in the heart, thereby exerting the effects of lowering blood pressure and reducing myocardial oxygen consumption. Clinically, it is mainly used for the treatment of hypertension, angina pectoris and myocardial infarction, and can also be used for symptom control of arrhythmia and hyperthyroidism. The applicable population covers adults and elderly patients with cardiovascular diseases who need blood pressure control.

As a classic cardiovascular drug that has been on the market for more than half a century, atenolol has a global market size of approximately USD 120 million, with its growth tending to be stable, and the market is dominated by generic drug supplies. In terms of the domestic market, the combined annual sales in public hospitals and retail channels exceed RMB 300 million, among which the demand for API is stable at around 60 tons per year. Domestic manufacturers are mainly generic pharmaceutical enterprises. A number of enterprises have passed the consistency evaluation of generic drugs and won bids in multiple rounds of provincial centralized procurement. The price is within a reasonable range, and the accessibility for patients is relatively high.

The original research enterprise of atenolol is AstraZeneca, and the original brand name is Tenormin. Its core compound patent expired globally in 1992. The main dosage form approved for the original research product is tablet, with specifications including 25mg, 50mg and 100mg. The original research preparation has been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. According to the domestic API registration platform, the atenolol APIs of more than 10 enterprises have obtained A-status registration numbers at present, and multiple domestic manufacturers have obtained approval for the marketing of atenolol tablets. (Data as of April 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of atenolol impurity reference standards, which can fully cover the requirements for impurity positioning and quantitative detection in the whole process of API R&D, quality research and registration declaration. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, providing reliable support for enterprises to improve R&D efficiency and ensure quality compliance.